Larotinib/Larotinib Instructions and Instructions for Use

Larotrectinib Trade nameVITRAKVI is a targeted therapy drug specifically used to treat patients with solid tumors carrying neurotrophic tyrosine receptor kinase (NTRK) fusion genes. The NTRK fusion gene is a relatively rare genetic change that is common in some types of tumors, including non-small cell lung cancer, soft tissue sarcoma, thyroid cancer, etc. Larotrectinib can effectively block the proliferation and expansion of tumor cells by selectively inhibiting the tyrosine kinase activity of the NTRK fusion gene, providing a new treatment option.

1. Indications and users

The indications for larotrectinib are mainly for the following types of patients: First, adult and pediatric patients with solid tumors who have been diagnosed withNTRK fusion genes through fully validated detection methods. Secondly, patients should have locally advanced or metastatic disease, and surgical resection may cause serious complications, or when conventional treatments are ineffective. These patients often have no satisfactory alternative treatment options or have failed previous treatments.

The application of larotrectinib is very specific and is mainly used for patients with NTRK fusion gene mutations, helping doctors to provide more precise treatments. By inhibiting the growth of tumors caused by NTRK gene fusion, the drug has significant therapeutic effects, especially for patients where traditional treatment options are ineffective or treatment options are limited.

2. Instructions for use

The recommended dosage of larotrectinib is oral administration, with dosages for adults and children varying. The recommended dose for adults is 100 mg orally twice daily until disease progression or unacceptable toxicity occurs. In pediatric patients, the recommended dose for pediatric patients with a body surface area ≥1.0 m2 is the same as for adults, 100 mg twice daily until disease progression or intolerable toxicity. For pediatric patients with a body surface area less than 1.0 square meters, the recommended dose is calculated based on body surface area and is 100 mg/m² taken orally daily in two divided doses.

Larotrectinib should be taken on an empty stomach, that is, avoid eating at least1 hour before taking it and at least 2 hours after taking it. This is because food may affect the absorption of the drug and affect its efficacy. Patients should be monitored regularly while taking larotrectinib, including assessment of liver and kidney function and observation for possible side effects. If a patient experiences adverse reactions or resistance to larotrectinib, doctors may adjust the drug dose or choose other treatment options.

3. Drug side effects

Although larotrectinib has shown good efficacy in clinical studies, like all drugs, it may also cause certain side effects. Common adverse reactions include but are not limited to fatigue, nausea, loss of appetite, abnormal liver function, headache, etc. Rarely, patients may experience more serious side effects, such as heart problems or neurological reactions. Therefore, during the treatment process, patients need to communicate closely with their doctors and report any discomfort symptoms in a timely manner.

Larotinib, as an innovative targeted drug, has significant efficacy, especially in patients with NTRK fusion gene-positive solid tumors. Its mechanism of action is clear, it can effectively inhibit the proliferation of cancer cells, and provides a new treatment option for patients who are ineffective in traditional treatments. Although the side effects of the drug are relatively mild, patients still need to pay close attention to possible adverse reactions during use and undergo regular examinations. Since larotrectinib is suitable for patients with positive NTRK fusion genes, it is necessary to accurately screen for gene mutations during treatment to ensure that the effect of the drug is maximized.

Reference materials:https://www.vitrakvi.com/